AzTrials
AzTrials

Multiple SclerosisPROGR-EXNCT06381440

Traditional Versus Progressive Robot-assisted Gait Training in People With Multiple Sclerosis and Severe Gait Disability

A study testing Lokomat device (Hocoma AG, Volketswil, Switzerland). and Conventional walking training in people with Multiple Sclerosis, run by University Hospital of Ferrara at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Multiple sclerosis (MS) is a demyelinating neurodegenerative disease. Qualitative alterations in walking function in MS people involve 75% of subjects with MS and are determined by reduced coordination, mobility, balance, and increased risk of falling. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Multiple Sclerosis
What is being tested?
Lokomat device (Hocoma AG, Volketswil, Switzerland). and Conventional walking training
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteItaly
Study dates
15 Nov 2023to 30 Nov 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of MS (primary or secondary progressive) without relapses in the preceding 3 months
  • Disability rate defined by Expanded Disability Status Scale (EDSS) score from 6 to 7
  • Ability to perform the Timed 25-Foot Walk (T25-FW) test
  • Mini-Mental Status Examination score ≥ 24/30

Who cannot join

  • Other (neurological) conditions that may affect motor function
  • Medical conditions might interfere with the ability to complete the study protocol safely
  • Presence of spasticity with a Modified Ashworth Scale (MAS) score > 3 or retractions limiting the range of motion of the hip, knee or ankle
  • MS relapses or medication changes or any other confounding factors during the study period
  • Rehabilitation treatment or botulinum toxin injection in the 3 months preceding the start of the study

Trial locations and contacts

1 site in 1 country.

Sofia Straudi, PhD contact

0532238720

sofia.straudi@unife.it

Italy1 site, 1 recruiting
  • Department of Neuroscience and Rehabilitation, University Hospital of Ferrara

    Ferrara, Emilia-Romagna, 44124

    Sofia Straudi, MD, PhD, 0532236185, s.straudi@ospfe.it

    Sofia Straudi, MD, PhD

    Recruiting

Other trials in Italy

About this study

Official title: Traditional Versus Progressive Robot-assisted Gait Training in People With Multiple Sclerosis and Severe Gait Disability: Study Protocol for a the PROGR-EX Randomized-controlled Trial

Multiple sclerosis (MS) is a demyelinating neurodegenerative disease. Qualitative alterations in walking function in MS people involve 75% of subjects with MS and are determined by reduced coordination, mobility, balance, and increased risk of falling. Robot assisted gait training (RAGT) devices seem effective in MS patients with severe motor disabilities, failing to show significant superiority when compared to intensive overground gait rehabilitation (OGT). This study aims to evaluate the effects of a low-intensity RAGT at progressively increasing intensity compared to conventional RAGT and OGT.

Read the detailed description

Gait disorders are the most frequent symptoms associated to multiple sclerosis (MS).Robot-assisted gait training (RAGT) in people with MS (PwMS) has been proposed as a possible effective treatment option for severe motor disability. Although RAGT continues to prove effective in increasing patient mobility, no significant superiority was found when compared to intensive overground gait rehabilitation (OGT). In PwMS, RAGT at high-intensity may enhance fatigue and spasticity, compromising the effectiveness and applicability of the intervention.

This study aims to evaluate the effects of a low-intensity RAGT at progressively increasing intensity compared to conventional RAGT and OGT in PwMS and moderate to severe walking impairment.

We will recruit 24 PwMS from the patients afferent to Outpatient Rehabilitation Clinic at University Hospital of Ferrara and we will assign them to one of the three treatment groups: low-intensity RAGT at progressively increasing intensity, conventional RAGT and OGT. All participants will receive 3 weekly treatment sessions of 3 hours each for 4 weeks. In the first 2 hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour, subjects will undergo specific gait training according to the assignment group. Subjects allocated to low-intensity RAGT at progressively increasing intensity group will receive gait rehabilitation on the Lokomat device and a speed initially set at 1.0 km/h, with progressive increments of 0.1 km/h at each training session. The working time consists of bouts of 3 minutes of work alternated by 1 minute of recovery, to be repeated 8 times. Subjects allocated to conventional RAGT will receive gait rehabilitation on the Lokomat device and the machine parameters will be determined based on the patient's characteristics. Subjects allocated to OGT will perform a 40-minute walk on a flat surface supervised by a physiotherapist. Outcomes will be assessed before and after treatment and at 3-month follow-up. The primary outcome is walking speed. Secondary outcomes include mobility and balance, psychological measures, muscle oxygen consumption, electrical and hemodynamic brain activity, urinary biomarkers, usability, and acceptability of robotic devices for motor rehabilitation.

Being tested
Lokomat device (Hocoma AG, Volketswil, Switzerland)., Conventional walking training
Keywords
Robot Assisted Gait Training, Mobility, Biomarkers
Medical subject headings
Multiple Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lokomat device (Hocoma AG, Volketswil, Switzerland).Device

    Robot Assisted Gait Training device

  • Conventional walking trainingOther

    Self-paced supervised walking training

Study groups in NCT06381440
Study groupRoleWhat they receive
Low-intensity RAGT at progressively increasing intensityExperimentalParticipants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, subjects allocated to this group will receive gait rehabilitation on the Lokomat device (Hocoma). The device in use will be set at 60% robotic assistance, 50% of load suspension, and a speed initially set at 1.0 km/h, with progressive increments of 0.1 km/h at each training session. The working time consists of bouts of 3 minutes of work alternated by 1 minute of recovery, to be repeated 8 times.
Receives: Device: Lokomat device (Hocoma AG, Volketswil, Switzerland).
Conventional RAGTActive comparatorParticipants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, subjects allocated to this group will receive gait rehabilitation on the Lokomat device (Hocoma). . In this case the parameters for setting the machine will be determined by the physiotherapist in charge for treatment administration in relation to the specific characteristics of the patient.
Receives: Device: Lokomat device (Hocoma AG, Volketswil, Switzerland).
Over ground training (OGT)Active comparatorParticipants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, the subject will perform a 40-minute walk on a flat surface, preceded by a warm-up phase and followed by a 10 minute warm-down phase each. Subjects will walk back and forth over a distance of approximately 30 metres using their walking aid.
Receives: Other: Conventional walking training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Walking function

    The walking function will be assessed by the T25-FW test

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

Secondary outcomes (17)
  1. Mobility

    Timed Up and Go (TUG) test

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  2. Walking endurance

    6-Minute Walk Test (6MWT)

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  3. Balance

    Berg Balance Scale (BBS), a 5-point ordinal scale used to assess the ability to maintain balance statically and while performing functional movements. BBS comprises 14 tasks; the total score is calculated by summing the scores of each item (0-4). The maximum total score is 56. Higher totals reflect more balance impairment.

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  4. Spasticity

    Modified Ashworth Scale (MAS), a 6-point measure of spasticity. The assessor will rate the perceived amount of resistance or tone at the flexor and extensor muscles of the hip, knee, and ankle. Higher scores reflect more spasticity

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  5. Perceived quality of life

    Multiple Sclerosis Impact Scale-29 (MSIS-29), a questionnaire that evaluates the impact of MS on physical and psychological functioning. It comprises 29 items, with 20 items assessing physical activity and 9 assessing psychological state. Each item can be rated from 0 to 5; the total score is the sum of all items. Higher score reflect higher impact of MS on quality of life.

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  6. Perceived walking ability

    Multiple Sclerosis Walking Scale-12 (MSWS-12), a questionnaire used to evaluate the impact of MS on walking ability. It comprises 12 items that inquire about the patient's perception of gait speed, running, confidence in ascending/descending stairs, balance, and fatigue. The total score is calculated by summing the scores of each item (0-5) and then converting it into a value ranging from 0 to 100. Higher score reflect higher impact of MS on walking ability.

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  7. Fatigue

    Fatigue Severity Scale (FSS), a short questionnaire that requires the subject to rate their level of fatigue from 1 to 7 in different activities. Higher score reflect higher impact of fatigue

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  8. Anxiety

    Beck Anxiety Inventory (BAI), a questionnaire used to measure anxiety levels, consisting of 21 items. Respondents indicate how severely each symptom affected them using a 4-point Likert scale, ranging from 0 (not at all) to 3 (severely). The sum of all responses provides an overall score, with higher totals reflecting more intense anxiety symptoms

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  9. Depression

    Beck Depression Inventory - II (BDI-II), a questionnaire comprised of 21 multiple-choice questions. Respondents assign a score ranging from 0 to 3 to each answer, where higher cumulative scores signal a greater severity of depressive symptoms

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  10. Kinesiophobia

    Tampa Scale of Kinesiophobia (TSK), a 17-item self-evaluation checklist on a 4-point Likert scale to assess the fear of movement or potential re-injury. The scoring yields a total raw score that can range from 17 to 68 and higher cumulative scores reflect higher fear of movement.

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  11. Adaptation to medical condition

    Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), a 46-item self-report tool designed to evaluate a patient's adaptation to either a current medical condition or the aftermath of a past illness. Each question within the PAIS-SR is scored on a scale from 0 to 3, where a higher score reflects a lower level of adjustment

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  12. Coping strategies

    Brief COPE, a self-report questionnaire used to evaluate coping strategies in facing stressful, unpredictable, and damaging events. It comprises 28 items grouped in 14 faced-scales which represent 14 different coping reactions. Respondents rate each item on a 4-point Likert scale, ranging from 1 (I haven't been doing this at all) to 4 (I've been doing this a lot). Total scores on each scale range from 2 (minimum) to 8 (maximum). Higher scores indicate increased utilization of that specific coping strategy.

    Measured: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  13. Muscle oxygen consumption

    The Near-infrared spectroscopy (NIRS) technology will evaluate muscle oxygen consumption. The patient, lying supine, will be fitted with a pair of NIRS sensors (transmitter and receiver) at the medial belly of the gastrocnemius to monitor changes in oxygenated and deoxygenated hemoglobin.

    Measured: Data changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  14. Hemodynamic cortical activation

    Hemodynamic cortical activation recorded during reaching and grasping activities performed with the most impaired (or not dominant) upper limb. Each patient will be equipped with a Near-infrared spectroscopy (NIRS) system composed of 16 sources and 16 detectors emitting two wavelengths of near-infrared light (760 and 850 nm). Hemodynamic signals will be recorded at a sampling rate of 3.81 Hz. A standard cap will be placed over each participant's scalp, and sources and detectors were positioned on the measuring cap according to the 10-20 international system with standard interoptode distances of approximately 3 cm. Optodes were placed over both hemispheres, resulting in 48 channels covering the regions of the primary motor and sensorimotor cortices. Data will be analyzed assessing the variations in oxygenated and deoxygenated hemoglobin

    Measured: Data changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  15. Electrical brain activity

    EEG recording during action observation task. Stimuli will consist in videos, filmed in the first person, in which a hand will show reaching for and grasping a can. The EEG will be recorded during the 20 minutes of the session: 3 minutes with open eyes, 3 minutes with closed eyes, and 14 minutes of video observation.

    Measured: Data changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

  16. miRNA expression

    Urinary lab examination

    Measured: Data changes before (T0) and after (T1) the twelve sessions of treatment.

  17. Acceptability of robot intervention

    Ad-hoc questionnaire with closed 1-10 Likert-scale and open-ended questions to assess patients' experience with the robot intervention. The questionnaire will specifically explore the usability, acceptability, perceived pleasantness, and safety of the intervention. Higher scores reflects higher satisfaction of the treatment.

    Measured: Scores registered after (T1) the twelve sessions of robotic treatment.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2024
  2. Study start15 Nov 2023
  3. Primary completion30 Nov 2024 (estimated)
  4. Study completion30 Nov 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized Control Trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06381440
Sponsor's protocol ID
PROGR-EX_MNESYS
Acronym
PROGR-EX
Status last verified
Jan 2024
First submitted
2 Apr 2024
Last updated
24 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Baroni A, Lamberti N, Perachiotti G, Crepaldi A, Piva G, Manfredini F, Straudi S. Low intensity interval robot-assisted gait training improves mobility in people with progressive multiple sclerosis: the PROGR-EX randomized controlled trial. Mult Scler Relat Disord. 2025 Dec;104:106777. doi: 10.1016/j.msard.2025.106777. Epub 2025 Sep 23.

    PubMed 41005019
  • Baroni A, Lamberti N, Gandolfi M, Rimondini M, Bertagnolo V, Grassilli S, Zerbinati L, Manfredini F, Straudi S. Traditional versus progressive robot-assisted gait training in people with multiple sclerosis and severe gait disability: study protocol for the PROGR-EX randomised controlled trial. BMJ Open Sport Exerc Med. 2024 May 21;10(2):e002039. doi: 10.1136/bmjsem-2024-002039. eCollection 2024.

    PubMed 38779575

Questions about this trial

What is this clinical trial studying?

A study testing Lokomat device (Hocoma AG, Volketswil, Switzerland). and Conventional walking training in people with Multiple Sclerosis, run by University Hospital of Ferrara at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Sofia Straudi, PhD (0532238720, sofia.straudi@unife.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Walking function (time frame: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06381440, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in